Search

Your search keyword '"J Römisch"' showing total 20 results

Search Constraints

Start Over You searched for: Author "J Römisch" Remove constraint Author: "J Römisch" Topic plasma Remove constraint Topic: plasma
20 results on '"J Römisch"'

Search Results

1. Comparative biochemical studies of fresh frozen plasma and pooled solvent/detergent-treated plasma (octaplasLG ® ) with focus on protein S and its impact in different thrombin generation assay set-ups.

2. Universal pooled plasma (Uniplas(®)) does not induce complement-mediated hemolysis of human red blood cells in vitro.

3. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG.

4. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time.

5. A biochemical quality study of a pharmaceutically licenced coagulation active plasma (Octaplas) thawed by the SAHARA-III dry tempering system compared to the regular use of a water bath.

6. Thrombin generation capacity is impaired in methylene-blue treated plasma compared to normal levels in single-donor fresh-frozen plasma, a licensed solvent/detergent-treated plasma (Octaplas) and a development product (Uniplas).

9. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development.

10. A biochemical comparison of a pharmaceutically licensed coagulation active plasma (Octaplas) with a universally applicable development product (Uniplas) and single-donor FFPs subjected to methylene-blue dye and white-light treatment.

11. Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing.

12. Prion removal effect of a specific affinity ligand introduced into the manufacturing process of the pharmaceutical quality solvent/detergent (S/D)-treated plasma OctaplasLG®

13. Biochemical quality of the pharmaceutically licensed plasma OctaplasLG®after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time

14. Comparative biochemical studies of fresh frozen plasma and pooled solvent/detergent-treated plasma (octaplasLG

16. Factor V Leiden-like behaviour of animal plasma and its use for calibration of activated protein C-dependent assays

17. Removal of prion infectivity by affinity ligand chromatography during OctaplasLG® manufacturing--results from animal bioassay studies

18. A biochemical quality study of a pharmaceutically licenced coagulation active plasma (Octaplas) thawed by the SAHARA-III dry tempering system compared to the regular use of a water bath

19. Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development

20. A biochemical comparison of Octaplas with a universally applicable development product (Uniplas) and single-donor fresh-frozen plasmas subjected to methylene-blue dye and white-light treatment

Catalog

Books, media, physical & digital resources